Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic.
View / Open Files
Publication Date
2022-01-20Journal Title
BMC Med Res Methodol
ISSN
1471-2288
Publisher
Springer Science and Business Media LLC
Volume
22
Issue
1
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Ewings, S., Saunders, G., Jaki, T., & Mozgunov, P. (2022). Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic.. BMC Med Res Methodol, 22 (1) https://doi.org/10.1186/s12874-022-01512-0
Abstract
BACKGROUND: Modern designs for dose-finding studies (e.g., model-based designs such as continual reassessment method) have been shown to substantially improve the ability to determine a suitable dose for efficacy testing when compared to traditional designs such as the 3 + 3 design. However, implementing such designs requires time and specialist knowledge. METHODS: We present a practical approach to developing a model-based design to help support uptake of these methods; in particular, we lay out how to derive the necessary parameters and who should input, and when, to these decisions. Designing a model-based, dose-finding trial is demonstrated using a treatment within the AGILE platform trial, a phase I/II adaptive design for novel COVID-19 treatments. RESULTS: We present discussion of the practical delivery of AGILE, covering what information was found to support principled decision making by the Safety Review Committee, and what could be contained within a statistical analysis plan. We also discuss additional challenges we encountered in the study and discuss more generally what (unplanned) adaptations may be acceptable (or not) in studies using model-based designs. CONCLUSIONS: This example demonstrates both how to design and deliver an adaptive dose-finding trial in order to support uptake of these methods.
Keywords
Phase I, Bayesian, Adaptive Design, Dose Escalation, Humans, Bayes Theorem, Maximum Tolerated Dose, Dose-Response Relationship, Drug, Research Design, Pandemics, COVID-19, SARS-CoV-2
Sponsorship
Medical Research Council (MC_UU_00002/14)
NIHR Academy (SRF-2015-08-001)
Medical Research Council (MR/V028391/1)
National Institute for Health Research (IS-BRC-1215-20014)
Wellcome Trust (221590/Z/20/Z)
Identifiers
PMC8771176, 35057758
External DOI: https://doi.org/10.1186/s12874-022-01512-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334290
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk